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Introduction: Periodic fever, aphthous stomatitis, pharyngitis, and cervical
adenopathy (PFAPA) syndrome is a non Mendelian autoinflammatory dis-
order until now considered to be specifically limited to paediatric age. How-
ever there is recently mounting evidence that children older than 5 years
and adults may present with the typical picture of PFAPA syndrome.
Objectives: We report the case of a 17,5 years old girl presenting
with recurrent episodes of fever starting at the age of 16.
Methods: A 17,5 years old girl was referred to our department due
to recurrent episodes of fever lasting 3–4 days and starting 1,5 year
ago. Body temperature usually increased up to 40.5∘C. Fever was ac-
companied by exudative pharyngitis, cervical lympadenopathy, se-
vere malaise and myalgias/artralgias. Oral apthosis was present in
some of the episodes. There was no other sign of upper respiratory
tract infection. Headache and fatigue were evident 2–3 days before
each flare.The episodes recurred very regularly showing an almost
clockwork periodicity (every 35–40 days). The girl was completely
asymptomatic between flares with normal growth and development.
The girl’s mother suffered from similar episodes of exudative pharyn-
gitis until approximately the age of 12.
Results: Laboratory exams during febrile attacks showed mild
leukocytosis with prominence of neutrophils and a significant increase
of monocytes. Erythrocyte sedimentation rate,C-reactive protein and
Serum Amyloid A were also raised. Serum immunoglobulin levels (in-
cluding IgD) were normal. During episodes all the cultures were negati-
ve.Inflammatory markers were completely normal between attacks.The
girl was diagnosed with PFAPA syndrome based on Marshall criteria re-
vised by Thomas et al.,neglecting the item of disease onset before the
age of five. Genetic testing for FMF is pending. Tonsillectomy was not
proposed as a therapeutic option because it seems not to be effective in
adults, based on current literature. A single dose of prednisone (1 mg/
kg) given a few hours after the onset of fever dramatically abrupted
fever attack in a few hours, supporting the diagnosis of PFAPA.The girl
did not experience a free interval shortening after steroid administration.© The Author(s). 2017 Open Access This artic
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/zeConclusion: Once thought to be exclusive of the pediatric age, it is
nowadays clear that PFAPA syndrome may have its onset in adulthood.
Clinical features of PFAPA adults are overlapping with those of PFAPA
children.To date, it is not known whether adults with PFAPA syndrome
may spontaneously undergo clinical remission, and tonsillectomy does
not seem to be a valid option in these patients. The description of
PFAPA syndrome in adults should increase awareness among clinicians
and suggests that the age criterion (i.e., age at onset less than 5 years)
should not be considered mandatory for diagnosis
Disclosure of Interest
None DeclaredDisease outcome
B2
Case of paraneoplastic arthritis in child
Olena A. Oshlyanska, Ludmila I. Omelchenko, Tatiana A. Ljudvik
Department of connective tissue disorders in children, State Institute of
Pediatrics, Obstetrics and Gynecology, Academy of Medical Sciences of
Ukraine, Kyiv, Ukraine
Correspondence: Olena A. Oshlyanska
Pediatric Rheumatology 2017, 15(Suppl 2):B2
Introduction: Differential diagnosis in children’s articular syndrome pre-
sents difficulties in actual practice. According to the clinical register of the
connective tissue separation diseases in children more than 20% of cases
with a primary diagnosis of JIA are overdiagnosis. Special attention should
be paid to arthritis in neoplastic processes, they are characterized by the
injury of one joint with severe pain syndrome and hematological changes.
Objectives: A description of the case of paraneoplastic arthritis.
Methods: Analysis of medical history
Results: Child Ts., A boy of 14 years. Anamnesis is not burdensome. For
3 months before hospitalization - an acute intestinal infection, after
3 weeks - pain and swelling of the right knee joint, subfebrilititis, NSAID
therapy 1 month without effect. On examination, swelling without local
hyperthermia of the right knee joint with minimal restriction of flexion,
“crunching” during movement, other joints are intact. Dryness of the skin
on the back surface of the hands, moderate difficulty in nasal breathing.
At physical examination no changes in internal organs revealed. At exam-
ination, the general blood test without pathological changes, ESR
10 mm/h, CRP negative. RF, ANA, APLAT, aDNA - not detected, serological
tests for pseudotuberculosis, iersiniosis, mycoplasmal and chlamydial in-
fections are negative, ASLO is normal. Elevated CIC 0.059 g/l, IgE in serum
(934 ng/ml), positive skin prik test for histamine, eosinophilia in the nazo-
cytogram and peripheral blood. ECG, ultrasound examination - without
changes. Ultrasound of the knee joint: exudative synovitis. Ultrasound ofle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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T4, TSH, ATPO are normal. A thin needle aspiration needle biopsy of the
thyroid gland was performed. Cytological study: pronounced prolifera-
tion and atypia of thyroid epithelium. Left-sided hemithyroidectomy
was performed. By the conclusion of a biopsy “papillary carcinoma of
the thyroid gland”. The child was examined 1.5 months after the oper-
ation. Clinical manifestations of arthritis of knee joints have not been
revealed. NSAIDs are canceled, receiving substitution therapy with thy-
roxine. There was swelling of the face and a one-sided enlargement of
the cervical lymph nodes, with their biopsy atypical cells that do not
morphologically correspond to the cells of the thyroid gland identified.
The CT of the whole organism was carried out - the primary localization
of the tumor was not established. The patient is currently observed at
the oncologist.
Conclusion: In some cases, arthritis develops earlier than the tumor
process is diagnosed. The clinician should pay attention to the lack of
typical clinical and laboratory signs characteristic of JIA and resistance
to anti-inflammatory therapy. Manifestations of allergization, like
arthritis, may be signs of a rheumatological paraneoplastic syndrome.
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Introduction: Chronic recurrent multifocal osteomyelitis (CRMO) as a
rare autoinflammatory disorder, affecting predominantly girls, is
sometimes associated with arthritis.
Objectives: Report of a patient with subsequent rheumatology diagnoses.
Methods: A case report of a 10-year-old girl with juvenile idiopathic
arthritis (JIA) with onset at the age of 1 year and 8 months, in remis-
sion on therapy (etanercept + methotrexate) presenting with new
clinical problems leading to subsequent diagnoses.
Results: At the age of 10 years, the girl presented with backpain last-
ing 2 weeks, swelling localized to thoracic region, elevated ESR, CRP,
and anemia. Whole body MRI revealed Th8/Th9 compressive fracture
and multifocal bone lesions. Clindamycine and Jewett corset were
recommended with discontinuation of immunosuppressive therapies.
Lesional biopsy, bone marrow aspiration and PET-CT did not show
malignancy. When intermittent fever appeared, blood culture re-
vealed Moraxella osloensis (confirmed by PCR) resistant to clindamy-
cine and antibiotics were changed and administered up to
14.5 weeks in total. Despite the slow clinical improvement the inter-
disciplinary discussions led to initiation of bisphosphonate therapy.
On intravenous pamidronate administered every 3 months (now
after the third course), her clinical status as well as imaging findings
are steadily improving, with no signs of arthritis.
Conclusion: Discussion: The following questions arise: Was it “only”
an atypical infection in an immunocompromised patient with JIA or
does the patient suffer from three rare diseases (JIA, subacute osteo-
myelitis by Moraxella osloensis, and CRMO)?
Parents agreed with presentation of patient’case, including
photodocumentation.
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Introduction: Foot and ankle pathologies are common in juvenile
idiopathic arthritis (JIA) and can cause physical disability and reduce
quality of life (1). Early detection and evidence-based treatment of
these symptomatic pathologies are an important first step in pre-
venting ongoing pain and long-term disabilities in children with JIA.
Objectives: To search the literature and provide an update on the
types of foot and ankle pathologies reported in children with JIA.
Methods: MEDLINE (Ovid) was searched for relevant papers pub-
lished in English with preference given to papers published in the
last 10 years, and older highly regarded cited papers.
Results: Foot and ankle pathologies are highly prevalent in JIA (1–3).
Foot and ankle pathologies in JIA include joint disease, tenosynovitis,
muscle atrophy, enthesitis, digital deformities and biomechanical ab-
normalities (1–9). One study surveying foot problems found that in a
cohort of 30 children with JIA, 63% reported some level of foot-
related impairment and 60% with foot-related participation restric-
tion (1). This review outlines and describes each of these foot and
ankle pathologies.
Joint disease – Joint disease in JIA may include joint swelling, tender-
ness, pain, warmth and stiffness (4). These symptoms typically occur
as a result of synovitis (4) and may be involved in 35-58% of cases
(2, 3, 5, 10).
Tenosynovitis – inflammation of the tendon sheath in JIA commonly
affects the tibialis posterior and peroneal tendons (5).
Muscle atrophy – Plantar-flexor muscle atrophy may be observed in
children with JIA. This may be more noticeable when there is active
joint disease in the ankle (6, 7). A reduction of plantar-flexion
strength at the ankle may have implications in the propulsive phase
of the gait, by delaying heel lift and increasing plantar pressures on
the rear and midfoot.
Enthesitis – Inflammation at the site of insertion of a tendon or
ligament to the bone is common at the Achilles tendon and the
medial tubercle of the calcaneus. These are typically seen in male
patients with the enthesitis-related subtype of JIA (4). One recent
study with 26 JIA participants (average age of 11.6 years) re-
ported a prevalence of 45% for the Achilles tendon and 20% for
the plantar fascia (8). The mean recorded pain on a 100 mm vis-
ual analogue scale was 48 mm (8). Quality of life was not mea-
sured in this study; however, this level of pain may reduce
physical and social well-being.
Digital deformities – Inflammation in the forefoot may lead to digital
deformities such as clawed toes in children and adolescents with JIA.
One study reported a prevalence of 17% in 144 participants (average
age = 10.6) with JIA and hallux abducto valgus (2). Children with
polyarticular subtype of JIA and those with a longer duration of dis-
ease were more likely to have hallux abducto valgus (2).
Biomechanical abnormalities – Biomechanical abnormalities of the
foot and ankle are associated with prolonged synovitis (3). Synovitis
can disrupt normal articulation of the rear and midfoot joints, and
can contribute to an excessively pronated foot and abnormal plantar
pressures (9). One study found that the prevalence of excessively
pronated rear and midfoot joints in 144 JIA participants, was 73%
and 72% respectively (2).
Conclusion: A range of foot and ankle pathologies are highly preva-
lent in JIA and contribute to physical morbidity. Allied health profes-
sionals may be involved as part of the paediatric rheumatology
multidisciplinary team to assist in the early detection and manage-
ment of these lower limb pathologies. Further research is required to
attain accurate prevalence rates and the long-term implications that
these foot and ankle conditions may have on a child or adolescent
with JIA.
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Introduction: Regulatory T cells (Treg) are essential regulators of self-
tolerance and are crucial for maintaining immune homeostasis. FOXP3
transcription factor is considered as a specific marker and the main
regulator for the differentiation and function of Treg cells. Juvenile Idio-
pathic Arthritis (JIA) is the most common rheumatic disease of child-
hood, and characterization of the specific subsets of Treg is essential to
unravel their role in the pathogenesis of juvenile idiopathic arthritis (JIA).
Objectives: CD4+CD25+FOXP3+ Treg cells, are some of the key
players in immunoregulation. This study was undertaken to investi-
gate the phenotype of CD4+ T cells in PBMCs from JIA patients in
two stages of clinical analyses, pre and post treatment and compare
them to a matched set of healthy controls.
Methods: The phenotypes of T cells of PBMCs from JIA patients and
matched controls were determined by flow cytometry. Treg suppres-
sion capacity was analyzed with a CFSE‐based T cell suppression
assay. Statistical analyses within and between the groups was per-
formed using SPSS.
Results: Treg number was quantified by analyzing CD4+CD25+FOXP3+
cells from peripheral blood samples. The proportion and suppression
capacity of regulatory T cells were different between the cases and con-
trols (pre-treatment cases vs controls P = 0,006, post-treatment cases vs
controls P = 0.001). With just one third of the data analyzed there were
slight quantitative differences in regulatory T cells between the case
and control groups but were not statistically significant.
Conclusion: Results shown here are not conclusive since this is an
ongoing study.
Disclosure of Interest
None DeclaredB6
A 10-year Saudi experience of using adalimumab in treating
Juvenile Idiopathic Arthritis
Mohammed A. Mozaffar, Asraa K. Turkistani, Samaa O. Sangoof
Pediatric, King Abdulaziz University Hospital, Facult of Medicine, Jeddah,
Saudi Arabia
Correspondence: Mohammed A. Mozaffar
Pediatric Rheumatology 2017, 15(Suppl 2):B6
Introduction: Traditionally, management of Juvenile Idiopathic Arth-
ritis (JIA) involves use of non-steroidal anti-inflammatory drugs
(NSAIDS) or disease-modifying anti-rheumatic drugs (DMARDs), such
as methotrexate (MTX) or sulfasalazine; or steroids. However, in sev-
eral cases, a low therapeutic response or important side effects are
encountered. This study reports our experience in using adalimumab
in JIA patients by assessing the efficacy and safety of this treatment
in this category of patients.
Objectives: To reports our experience in using adalimumab in JIA pa-
tients by assessing the efficacy and safety of this treatment in this
category of patients.
Methods: A retrospective study was conducted among 38 patients
with JIA at the Pediatric Department, King Abdulaziz Univesrity Hos-
pital, Jeddah, Saudi Arabia, in the period January 2005 - March 2016.
Patients’ records were reviewed and relevant demographic and clin-
ical data were collected. Data were analyzed using SPSS version 21
and represented using tables.
Results: The 38 patients were distributed as 11 (28.9%) males and 27
(71.1%); mean ± SD age was 11.91 ± 4.54 (range = 3 – 19) years.
Mean ± SD (range) disease duration was 3.26 ± 2.52 (0–12) years and
most frequent diagnoses included polyarticular rheumatoid factor
(RF) negative form 12 (31.6%), followed by systemic and oligoarticu-
lar JIA with 9 (23.7%) cases each. Before adalimumab,fever was
present in 13 (34.2%) cases, followed by rash in 8 (21.0%) cases;
while 21 (55.3%) were asymptomatic. Thirty-one (81.6%) were in fail-
ure of MTX, 19 (50%) of steroids, 7 (18.4%) of NSAIDS and 3 (7.9%)
had had intraarticular injections. Biologically, ANA, RF and anti-CCP
were positive in 22 (57.9%), 8 (21.1%) and 4 (10.5%) of the cases, re-
spectively. Uveitis was present in 11 (28.9%) of the patients. Analysis
of adalimumab efficacy showed 10 (52.6%) cases of complete remis-
sion, 9 (23.7%) of partial remission and 9 (23.7%) other where treat-
ment was discontinued. Major adverse effects included local pain (4
[10.5%]), new onset uveitis (1 [2.6%]) andrash (1 [2.6%]), responsible
of 1case of treatment discontinuation. Predictors for complete remis-
sion on adalimumab were oligoarticular form (β = 3.450, p = 0.009)
and negative RF (β = 2.381, p = 0.036); while predictors for nonre-
sponse, whether complete or partial, were polyarticular form (β =
−3.784, p = 0.005) and positive anti-CCP (β = −3.178, p = 0.021).
Conclusion: Adalimumab is an efficient and relatively safe alternative
in the treatment of JIA with relatively high remission rates and lower
rates of adverse effects. Further multicentre experiences are war-
ranted to prove its efficacy and safety in the Saudi patients.
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Introduction: In recent years, the problems of children’s rheuma-
tology have become one of the most important areas of
pediatrics. In the treatment of juvenile idiopathic arthritis (JIA),
from the end of the 20th century, truly revolutionary progress is
being made, thanks to the emergence of gene-engineering bio-
logical therapy.
Pediatric Rheumatology 2017, 15(Suppl 2):59 Page 180 of 191Objectives: to analyze the structure of bDMARD and csDMARD
therapy in patients with different JIA subtypes residing in
Moscow.
Methods: The research included 262 patients residing in Moscow
aged from 1 year up to 17 years with rheumatic diseases treated by
bDMARDs. From them boys are 80 (30,5%), girls are 182 (69,5%),
mean age is 10 years (3–17).
The following parameters was analysed: subtypes of JIA preva-
lence, structure of bDMARDs; concomitant csDMARDs therapy.
Results: In total there are 262 children receive bDMARDs in Moscow
for 01.12.2016. Among them 123 (46,9%) suffer from RF(−) polyarthri-
tis, 62 (23,7%) - oligoarthritis, 53 (20,2%) - systemic arthritis, 9,2% -
other JIA forms.
2. Structure of bDMARDs in JIA.
TNF-inhibitors prevail over other biologics in children (etanercept
and adalimumab – 71,8%). Of 262 treatments the most frequent
bDMARDs are etanercept - 47%, and adalimumab– 24,8%.
19,9% of patients are treated with tocilizumab and 8,3% with
abatacept.
3. Structure of concomitant csDMARDs in JIA
Most of children – 73,3% (192 patients from 262) receive a
concomitant therapy by various medicines. Dominating majority
of patients receive methotrexate (80,8% of all children receiving
csDMARDs).
Conclusion: 1. TNF-inhibitors prevail in biologic therapy in children
an age from 1 to 17 years with JIA, etanercept - 47%, adalimumab–
24,8%.
2. Majority of patients receive methotrexate as a concomitant ther-
apy (80,8% of all children with JIA).
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Introduction: Juvenile dermatomyositis (JDM), the most common in-
flammatory myopathy of childhood, is a rare multisystemic auto-
immune vasculopathy, primarily affecting the skin and skeletal
muscles.There is mounting evidence that WBMRI can provide invalu-
able information in the management and following up of JDM pa-
tients by evaluating the true extent and inflammatory activity of
muscle disease.We report the case of a 5,5 year old girl with JDM
and extensive muscle involvement undetected during clinical exam-
ination and revealed by WBMRI
Objectives: We report the case of a 5,5 year old girl with JDM and
extensive muscle involvement undetected during clinical examin-
ation and revealed by WBMRI
Methods: A 5,5 year old girl presented to our department due to
a severe cutaneous eruption and fatigue during the last month.
Clinical examination revealed an erythematous, papulosquamous
eruption over dorsal surfaces of the knuckles, extensor aspects of
the elbows and knees (Gottron’s papules),a malar rash and re-
duced muscle strength involving mostly the upper body.Musclestrength was assessed using both the Childhood Myositis Assess-
ment Scale (CMAS 38/52) and Manual Muscle Test 8 test (MMT 8
55/80).
Results: Laboratory work up revealed a significantly increased creat-
ine kinase, lactate dehydrogenase, aldolase, alanine aminotransferase,
aspartate aminotransferase and a moderate increase of inflammatory
markers (ESR,CRP).Antinuclear antibodies were positive (1/320)
whereas all myositis-specific antibodies (MSAs) tested were negative.
WBMRI showed increased signal intensity on T2 and STIR images in
almost all muscles of the body and increased signal intensity in the
subcutaneous fat tissue of the arms. Intriguingly, WBMRI revealed dis-
tal legs and forearm muscle inflammation undetected during clinical
examination. Nailfold capillaroscopy demonstrated significant drop-
out, dilatation and tortuosity of nailfold capillaries. Based on the
pathognomonic rash and characteristic findings on WBMRI and nail-
fold capillaroscopy the diagnosis of JDM was established and inva-
sive diagnostic procedures such as muscle biopsy and EMG were
avoided. Aggressive treatment was initiated with both high doses of
steroids (pulses of methylprednisolone 30 mg/kg, on 3 consecutive
days followed by daily oral prednisolone 2 mg/kg) and high weekly
dose of subcutaneous methotrexate. At present, one month after
therapy initiation muscle enzymes are within normal range and
muscle strength is slightly ameliorated.
Conclusion: One of the major challenges in JDM clinical manage-
ment is to accurately assess disease activity. The potential of muscu-
loskeletal MRI as a non-invasive imaging procedure for defining
inflammatory activity of involved muscle is well established and pel-
vic/thigh MRIs are extensively used. WBMRI screens the entire body
with the advantage of evaluating much larger areas of muscles as
well as subcutaneous fat tissue, thus providing a complete assess-
ment of total muscular inflammatory burden. This is of utmost im-
portance for the therapeutic optimization in order to prevent further
damage Even though WBMRI value has been suggested in small
series of JDM patients, its real potential in JDM remains to be
explored.
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Introduction: Macrophage activation syndrome (MAS) is a known
complication of pediatric rheumatic disorders, particularly juvenile
idiopathic arthritis (JIA), systemic lupus erythematosus (SLE) and
Kawasaki disease (KD). MAS is a life-threatening condition with a
mortality rate of up to 20%. Therefore, early recognition and immedi-
ate therapeutic intervention are critical.
Objectives: To describe patient demographics, interventions and out-
comes in hospitalized children with MAS complicating SLE, JIA or KD.
Methods: Retrospective cohort study of the Children’s Hospital of
Mexico Federico Gomez, January 2013 to April 2017. Participants had
diagnosis for MAS and either SLE, JIA or KD. The primary outcome
was hospital mortality. Secondary outcomes included intensive care
unit admission, critical care interventions, and medication use.
Results: Seven children met inclusion criteria, including 4 with SLE, 2
with systemic JIA and 1 with Kawasaki disease. Index admission mor-
tality was 28% (2/7). ICU admission (100%), mechanical ventilation
(71%), and inotrope/vasopressor therapy (85%) were common. Com-
pared to children with JIA, those with SLE had higher mortality and
more ICU care [higher mechanical ventilation duration (10 days vs
2 days, and more time cardiovascular dysfunction]. Children with SLE
and JIA received glucocorticoids and cyclosporine at similar rates,
Pediatric Rheumatology 2017, 15(Suppl 2):59 Page 181 of 191but more children with SLE received cyclophosphamide and etopo-
side. One patient with SLE received etanercept (Anti-TNFa) and an-
other patient with SAM secondary to Kawasaki disease did not need
ICU or vasopressor therapy.
Conclusion: Organ system dysfunction is common in children with
rheumatic diseases complicated by MAS, and children with under-
lying SLE require more organ system support than children with JIA
Current treatment of pediatric MAS varies based on the underlying
rheumatic disease. In Mexico, the incidence rate of macrophage acti-
vation syndrome secondary to Kawasaki disease is less frequent, the
only patient included in this study had a clear clinical and laboratory
improvement after treatment with glucocorticoid alone.
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Introduction: Erythema nodosum (EN)is the most common panniculi-
tis in childhood. The lesions of EN are localized at the lower limbs, in
particular in the pretibial region, while upper limbs and trunk are
rarely involved. Erythema nodosum can be associated with general
symptoms such as fever, weakness, and severe pain, but skin lesions
resolve without skin damage.
Objectives: To describe five cases of Erythema nodosum in
childhood
Methods: R.G. f. 3 years old came to our department for a two week
history of fever (up to 38 °C) and skin lesions. Physical examination
revealed pharyngeal hyperemia and multiple erythematous nodules
on the extensor surface of the lower extremities. Laboratory tests
showed an elevation of ESR(35 mm/h) and CRP, (1,06 mg/dL) and
high levels of Chlamydia Pneumoniae IgM.Throat swab was negative
for group A beta-hemolytic Streptococcus (GAS) and her chest X-ray
was negative. So antibiotic therapy was prescribed and symptomatol-
ogy improved.
A.N. m. 8 years old was hospitalized for fever up to 39 °C and skin le-
sions in the lower limbs. Patient suffered from recurrent abdominal
pain and diarrhea. Physical examination revealed abdominal pain
and erythematous and painful nodules in pretibial region of both
lower limbs. Blood tests showed increase of ESR (40 mm/h) and CRP
(1,3 mg/dL). Blood examinations for celiac disease were negative.
Fecal calprotectin was high (500 mg/kg). Abdomen ultrasound re-
vealed terminal ileum bowel wall thickening. Crohn’s Disease (CD)was
suspected and confirmed with an endoscopy including biopsies.
A.N. f. 5 years old was admitted to our department for fever (38 °C)
and skin lesions that started two weeks ago. The patient also had
1 month history of cough. Physical examination revealed: pharyngeal
hyperemia, cervical and axillary lymphadenopathy and skin lesions
suggestive of erythema nodosum on the extensor parts of both
lower limbs. Inflammatory tests were increased (ERS 28 mm/h, CRP
1,5 mg/dL). Her chest X-ray was negative. Mantoux test was positive
with an induration of 15 millimeters (mm) after 48 hours and 18 mm
after 72 hours, also a Quantiferon test was positive.
L.B. f. 12 years old had an history of fever, headache, fatigue, joint
pain and skin lesions.The objective examination revealed: malar rash,
arthritis of the right knee, erythematous nodules on the extensor sur-
face of the lower limbs. Blood tests showed anemia (Hb,5 g/dL),
thrombocytopenia (PLT 75.000/mm3), ERS increased (30 mm/h) posi-
tive ANA, antiDNA. Systemic Lupus Erythematous was diagnosed ac-
cording to ACR criteria
I.L. f. 8 months old had a two months history of recurrent fever and
skin lesions. On admission the patient was febrile (TC 38 °C). Physical
examination revealed pharyngeal hyperemia, splenomegaly anderythematous nodules on the extensor surface of the lower limbs.In-
flammatory tests were increased (ERS 33 mm/h, CRP 2 mg/dL). Anti-
bodies anti CMV, EBV, Chlamydia and Mycoplasma Pneumoniae were
negative. Biopsy of a lesion showed a condition compatible with
panarteritis nodosa.
Results: EN is a skin inflammatory reaction. EN could be associated
with infectious diseases (GAS, Chlamydia Pneumoniae, Mycoplasma
Pneumoniae, Epstein-Barr virus, Mycobacterium Tuberculosis), drugs, in-
flammatory bowel diseases, rheumatologic diseases, malignant tumor.
Conclusion: The presented cases show that erythema nodosum can
be secondary to different diseases.In the diagnostic process associ-
ated symptomatology and laboratory tests should be considered to
diagnose the disease and to start specific treatment.
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Introduction: The following observations were made from 25 years
of practice in Paediatric Rheumatology
Objectives: To share these observations to assist others in their prac-
tice and to facilitate collaborative research and audit
Methods: Review of case data
Results: 1. The cause of symptoms in Benign Joint Hypermobility
Syndrome relates to children today being physically weak as mea-
sured by manual muscle testing (Oxford scale) compared to typical
children a generation ago.
2. Chronic Fatigue Syndrome only occurs in children who are hyper-
mobile and weak.
3. Bottom shuffling is a feature of children with hypermobility.
4. W sitting is only seen in hypermobile children as hips can intern-
ally rotate 90 degrees and is a safe way to sit
5. Left handedness is only seen in hypermobile children who are clin-
ically right hand dominant but write with their left hand
6. Writing difficulties relate to the fact that grip strength in children
is now one third of children a generation ago and not related to pen
grip
7. Children sit in a kyphotic posture due to poor core muscle stamina
and when sat up straight their left shoulder is higher and narrower
than their right due to trapezius muscle spasm
8. Intoeing, outoeing and tip-toe gait often relates to hypermobility
and supple subtalar joints.
9. Children with hypermobility in general have higher levels of anx-
iety than non-hypermobile children. This often leads to symptoms
such as abdominal pain.
10. Flat feet are associated with hypermobility and with modern
weakness and needs to be corrected with orthotics
Conclusion: Hypermobility, which is a normal variant in society, is
now associated with a number of problems mostly due to inactivity
and weakness in children. These observations should help others in
their practice and be the foundation for further research.
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Table 1 (abstract B13) Clinical characteristics of two paediatric patients
diagnosed with mixed connective tissue disease
Symptoms at
disease onset
Laboratory
examinations
Capillaroscopy Anti-RNP
antibodies
Diagnosis
Case
1
Arthritis
Arthralgia
ANA 1/2560
ESR 54 mm/h
CRP 80.55 mg/dL
RF 49.9 UI/mL
Lymphopenia
Compatible with
MCTD
Positive MCTD
Case
2
Raynaud’s
Disease
ANA 1/2560
Positive Anti-Ro
antibodies
C4 9 mg/dl
ESR 28 mm/h
Lymphopenia
Sclerodermiform-
like
Positive MCTD
ANA antinuclear antibodies, ESR erythrocyte sedimentation rate, CRP C-reactive
protein, RF rheumatoid factor, MCTD mixed connective tissue disease
Pediatric Rheumatology 2017, 15(Suppl 2):59 Page 182 of 191Introduction: Neuromyelitis optica (NMO) is a central nervous system
inflammatory disease characterized most often by optic neuritis (ON)
and/or transverse myelitis (TM) along with serum immunoglobulin G
antibodies that target the water channel aquaporin-4 (AQP4-IgG).
The treatment of this condition is not standardized and may be chal-
lenging (1).
Objectives: To describe the first child with NMO, and also Sjogren’s
Syndrome (SS), successfully treated with the IL-6 receptor humanized
monoclonal antibody, tocilizumab.
Methods: Case report
Results: A 23 month old Caucasian male developed prolonged seiz-
ure in the setting of hyponatremia, resolved with hypertonic saline
administration. Brain MRI revealed T2 hyperintense lesions involving
the brainstem and thalamus. He was diagnosed with central pontine
myelinolysis (CPM) and achieved symptomatic remission after treat-
ment with intravenous immunoglobulin (IVIG) and intravenous meth-
ylprednisolone (IVMP). Two years later, he developed unilateral acute
ON on his right eye, completely resolved following IVMP.
At 11 years, he had an episode of ON in his left eye. There was con-
cern that his presentation could be consistent with NMO, and his
serum was positive for anti-AQP4-IgG at that time. Work up revealed
positive antinuclear antibody (ANA 1:160) and positive SS-A anti-
bodies, but lip biopsy was inconclusive for SS. Once more, he was
treated with IVMP, followed by oral corticosteroids.
At 14 years, the subject developed left-sided vision loss, right hemi-
paresis, and lethargy. He did not improve with IVMP, but did respond
to subsequent PLEX. MRI demonstrated ongoing disease activity with
a new large, confluent left-sided supratentorial white matter lesions
and confluent T2 hyperintense lesions of the thoracic cord (T2-T5).
Given the progression, he was treated with Cyclophosphamide (Cyc)
and Rituximab (RTX). After 5 Cyc infusions, he was transitioned to
Mycophenolate Mofetil (MMF).
Three months later, he had resolution of spinal involvement on MRI
without progression of brain lesions. His MRI incidentally revealed
numerous parotid cysts. Given the presence of parotid cysts, positive
SSA antibodies and mild symptoms of dry mouth, a diagnosis of SS
was made and hydroxychloroquine treatment was started. Over the
next two years, he relapsed several times and was treated with IVMP
and RTX. He later developed secondary hypogammaglobulinemia
and began IVIG replacement. Despite complete CD19+ B lymphocyte
depletion (absolute CD19+ ≤ 2 cells/μl), the relapses occurred with
shorter inter-treatment intervals. Therefore tocilizumab was added
when he was 16 years old. He was able to discontinue oral cortico-
steroids within 1 year. Rituximab was stopped after 4 rounds in two
years. Over a follow-up period of three years, he has not experienced
any relapses, despite absolute CD19+ > 100 cells/μl. He has not de-
veloped any adverse effect during ongoing treatment.
Conclusion: Blockade of IL-6 may be useful and safe to treat children
NMO. RTX is used to treat NMO but it is not always effective. A re-
cent report demonstrated that CD20− plasmablasts (PB), a population
not directly impacted by RTX, are increased in the peripheral blood
of patients with NMO, and that IL-6 can promote PB survival and
anti-AQP4 production in vitro (2). As IL-6 levels are increased in sera
and cerebrospinal fluid of patients with active NMO, IL-6 has been
hypothesized to be involved in the disease’s immunopathogenesis
(3). This may explain why inhibition of the IL-6 pathway can be a
valuable option to treat NMO. In this study we describe a pediatric
patient who, despite complete depletion of CD19 + B-lymphocytes,
did not maintain durable remission with RTX whereas remission on
tocilizumab was maintained also after B-cell repopulation.
1. Wingerchuk DM, Banwell B, Bennett JL, et al. International consen-
sus diagnostic criteria for neuromyelitis optica spectrum disorders.
Neurology 2015;85:177–189.
2. Chihara N, Aranami T, Sato W, et al. Interleukin 6 signaling pro-
motes anti-aquaporin 4 autoantibody production from plasmablasts
in neuromyelitis optica. Proc Natl Acad Sci USA 2011;108:3701–3706.
3. Uzawa A, Mori M, Arai K, et al. Cytokine and chemokine profiles in
neuromyelitis optica: significance of interleukin-6. Mult Scler
2010;16:1443–1452.
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Introduction: Mixed connective tissue disease (MCTD) is one of the
most infrequent rheumatic disorders in children and gathers clinical
features of juvenile idiopathic arthritis (JIA), systemic lupus erythema-
tosus (SLE), juvenile dermatomyositis (JDM), and cutaneous systemic
scleroderma (CSS). Esophageal dysmotility and cardiopulmonary in-
volvement may occur during the disease course, being the latter
which determines morbidity and mortality.
Objectives: To describe the main characteristics of two pediatric pa-
tients diagnosed with MCTD and substantially different clinical symp-
toms at disease onset.
Methods: Clinical charts review
Results: Two patients were included, both girls (case 1 and case 2),
whose main characteristics are described in Table 1. Age at disease
onset was 9 and 10 years old respectively. Delay of diagnosis ranged
between 2 and 3 years. Case 1 was initially diagnosed with positive
rheumatoid factor JIA, and case 2 with SLE (being Raynaud
phenomenon the main symptom). Inmunology studies were com-
pleted by anti-RNP antibodies determination, which were positive in
both cases. Both patients met Kasukawa criteria for MCTD. Capillaro-
scopy showed EMTC pattern in case 1 and sclerodermiform pattern
in case 2.
Both patients receive hydroxychloroquine and mycophenolate mofetile.
Conclusion: A wide variability exists regarding clinical onset of
pediatric MCTD and delay of diagnosis is common. Further research
is needed in order to validate paediatric classification/diagnostic
criteria.
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Introduction: Complex regional pain syndrome (CRPS) is a neuro-
pathic disoder characterized by chronic pain of unknown cause that
Pediatric Rheumatology 2017, 15(Suppl 2):59 Page 183 of 191associates sensorial, autonomic and motor symptoms. It is an under-
diagnosed entity that requieres a multidisciplinary approach. Cur-
rently there are no standarized treatment protocols.
Objectives: To describe clinical and epidemiological features of CRPS
patients and to analize factors potentially involved in evolution and
therapeutic response.
Methods: Descriptive retrospective study in CRPS patiens (diagnosed
accoding to Budapest criteria) younger than 14 years monitored by a
Pediatric Rheumatology Unit between January 2009 and February
2017.
Results: 15 patients were enrolled, 11 women mean age 10,82 years
(±1,7 SD). Among possible triggers we found previous trauma in 12
patients (11 were inmovilized with a median duration of 20 days)
and we identified unfavorable psychological factors in 7 patients. All
of them showed unilateral lower limbs involvement, except for one
patient with bilateral affection.
In terms of clinical symptoms, 14 presented functional impairement,
13 neuropathic pain (associated to allodynia in 10) and 5 trophic
changes. None of them had hypertrichosis. The mean time of diag-
nosis delay was 55,1 days (±63,2 SD). Magnetic resonance was per-
formed in 14 patients and showed pathologic findings in 9. Bone
scintigraphy was performed in 12 patients, being diagnostic (hyper-
caption in early phase) in 8.
Before the diagnosis was done all the patients received NSAIDs with-
out improvement. After the diagnosis everyone began physiotherapy
and pharmacologic treatment: pregabaline in 12, minor opioids in 8
and topical capsaicine 8% in 4. Due to refractoriness, a bupivacaina
epidural catheter was used in 3 patients.
Currently, 9 patients has no symptoms, with a median time of reso-
lution of 267,8 days (IQR:135–330) and 6 patients are still being mon-
itored because of persistent symptoms, with a median time of
evolution of 246 days (IQR: 94–342).
At the bivariant analysis no relation was found between time until
resolution and duration of immobilization neither unfavorable psy-
chological factors, but we found a strong possitive correlation with
the time of diagnostic delay (Rho: 0,85; p = 0,007).
Conclusion: Frequently there is a trauma history in CRPS in children
but it is not always present.
Althoug imaging tests are really helpfull to establish the diagnosis,
sometimes they do not show any changes.
It requires a multidisciplinary approach with physiotherapy and anal-
gesia as the fundamental basis of it.
The presence of desfavourable psycological factors in nearly a half of
patients makes it essential a professionalized aproach to this level to
manage an adequate control of the disease.
An early diagnose determines a faster clinical resolution, that is why
a high suspicion rate is needed.
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Introduction: Synovial haemangioma is a rare type of tumor which
affects the knee joint. Patients who are usually female and their sec-
ond decade of life, often apply nonspesific symptoms like pain and
limitation of motion. When this uncommon tumor is untreated, it can
cause cartilage erosion and degenerative joint disease. Because of its
rarity, physician awareness is low that results in delayed diagnosis.We presented a synovial haemangioma of the knee to increase
awareness of pediatricians.
Objectives: Clinical case
Methods: A 17-year-old girl was admitted to Erciyes Unversity Faculty
Of Medicine Peidatric Rheumatology in January 2017 with complaints
of pain, swelling and tenderness in her left knee.
Results: A 17-year-old girl was admitted with complaints of pain,
swelling and tenderness in her left knee since she was 3 years old.
With the previously magnetic resonance imaging of the knee joint,
she was diagnosed as chronic arthritis on the knee joint. Non-
steroidal anti-inflammatory drugs were recommended. Patient ap-
plied to our hospital because of ongoing complaints. There was no
any arthritis finding including tenderness, pain on motion, deformity,
and limitation of motion. On the upper part of left knee, she had lo-
calized swelling measuring 3,5x4 cm in diameter. Magnetic reson-
ance imaging (MRI) showed synovial haemangioma characterized by
a well-circumscribed contour with a lobule filling the left suprapatel-
lar bursa and space- filling formation with heterogeneous intense
contrast enhancement after contrast agent administration. It was re-
quired open total synovectomy and mass resection, and histopatho-
logical findings were compatible with cavernous haemangioma.
Conclusion: Tumor and tumor like lesions such as synovial haem-
angiomas should be kept in mind in patients with arthritis- compat-
ible findings in single joint. In case of doubt, especially intra-articular
lesions, imaging methods should be used for early diagnosis and pre-
vent long term sequel.
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Introduction: Rheumatic manifestations are not uncommon compli-
cation of jejunoileal bypass in treating morbid obesity, but also in
other conditions without reduction of lenght small intestini. Patho-
genesis is poorly understood, but overgrowth of intestinal bacteria
may play causative role.
Objectives: To present unusual case of reactive arthritis
Methods: data from the medical history
Results: We are presenting 18 months old girl at the first admission
in our clinic, with signs of arthritis appeared 14 months after bowel
resection due to prenatal volvulus. She was underwent to the surgi-
cal procedure in the first day after birth, and jejunoileal anastomosis
was done, leaving only 9 cm small intestine, ileocoecal valve was
spared. Febrile episode with symptoms of mild respiratory infection
proceeded to rheumatologic manifestation a few days before that.
Personal history: weight at the birth 3400 g, Apgar score 8/9, delivery
on time, not vaccinated, total parenteral nutrition for 7 months, after
that time special diet was conducted. Clinical examination showed
malnourished girl (8350 g below P3), not walked alone, otherwise
healthy, with evident polyarthritis: left wrist, MCP and PIP on the left
hand, both knees, left ankle, dactylitis of II finger of the left foot and
limited range of motion in left MTP area. Arthritis was confirmed by
ultrasound examination. There were no any skin changes, the belly
was meteoristic, but liver and spleen were within normal range.
Results of the laboratory tests showed: CRP 73,6 mg, ESR 16 mm/h,
WBC 12,4 x 109/L, Hb 130 g/l, PLT 324 x 109/L, IgM 3,02 g/L and IgG
17,5 (above upper limit) with elevation of all subclass of IgG, HLA
-A1, 32, B35.
Results of the following laboratory studies were normal: blood cultures,
culture throat and urine, for hepatitis B surface antigen, antibody to
hepatitis A virus, rheumatoid factor, C4, C3, total complement, ANA,
ANCA, C3, C4, CIC, IgA. Several samples of urine revealed hematuria.
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after consultation with nephrologist was changed with sulfameth-
oxazole/trimetoprine 5 mg/BW, which she continued to take at
home. Probiotic and loperamide were standard medication after
surgical procedure, and ibuprofen was added due to arthritis. On
the day of discharge from hospital, after 15 days from admisison,
the girl was in good condition, with normal laboratory analysis,
without any signs of arthritis. Hematuria was explaned by hypercal-
ciuria due to malabsorptional syndrome, and potassium citrate was
introduced for prevetion of hypercalciuria. Several motnhs later
rickets was confirmed clinicaly and by x-ray, and vitamin D suple-
mentation was added. Up to now the girl had several relapses of
arthritis, with limited duration, resolving of symptoms for a few
days. She has normal renal function, temporary hipercalciuria, mild
low mass wieght proteinuria and propensity to hiperoxaluria. Re-
peated diarrhea is the main problem sometimes leading to meta-
bolic acidosis and requiring antibiotic treatment.
Conclusion: We report the patient with unusual type of reactive
arthritis. To our best knowledge this is the youngest patent
with bypass syndrome so far published. Prophylactic treatment
with antibiotic has been showed good results in suppressing
joints inflammation, however this is self-limiting condition.
Other manifestations of malabsorption require serious approach
and treatment.
We thank to the parents for cooperation. A written consent was
obtaned for the publication of the case report.
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Introduction: Children’s experiences of fear and pain from hospital
visits could result in subsequent visits feeling even more daunting
and negative experiences could follow the child into adulthood. Earl-
ier studies shows that preparing and distraction in a playful manor
could decreased the child’s experience of pain and fear during a
painful procedure. Parents and children should be involved in dis-
traction and communication about the child’s care. The nurse has, to-
gether with the child, responsibility to select the distraction method
and show how to use it.
Objectives: To describe nurses’ experiences of distraction associated
with painful and unpleasant procedures in pediatric care.
Methods: Descriptive study design using qualitative interviews with
six nurses from pediatric care were conducted. To process the data
qualitative content analysis was used.
Results: The result could be divided into two categories; individu-
alized care and interaction. The result were clarified of nine
subcategories.
Conclusion: The nurse’s used distraction in almost all the painful pro-
cedures that children went through. Individualized distraction, safety,
allocating time and participation of the child was crucial for effective
distraction. Honest communication and sensitivity to the child’s expe-
riences created the conditions for a good interaction. Cooperation
with parents and colleagues helped the distraction process for child
and nurse. Evaluation of the distraction was made by assessing the
child’s body language.
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Introduction: in recent years a number of studies showed a connec-
tion between intestinal dysbiosis and various immunological dis-
eases, hence it is not coincidence gastrointestinal abnormalities can
often be found in patients with rheumatic diseases and musculoskel-
etal symptoms are not rare in variety of digestive system disorders.
Nevertheless, when both musculoskeletal and gastrointestinal symp-
toms presents simultaneously at the beginning of the disease, it
might be difficult to distinguish the primary disorder.
Objectives: to present a patient with simultaneous presentation of
characteristic gastrointestinal and musculoskeletal symptoms.
Methods: case report.
Results: a thirteen year old boy with medical history of infantile colic
and a brother with HLA B27 positive juvenile spondyloarthritis was
admitted to our department due to persistent inflammatory lumbo-
sacral pain, Achiles enthesitis, and abdominal discomfort. During the
six months period prior to the admission he had six episodes of
fever, cough, abdominal pain and aphthae lasting for few days. Acute
surgical disease was excluded on several occasions. Chest radio-
graph, throat and nose cultures showed no signs of infection. During
the last few episodes he developed swelling of the right talocrural
joint which resolved after short course of NSAID. Later, severe pain in
sacroiliac (SI) joints with morning stiffness emerged, while his stools
became loose and frothy. Abdominal ultrasound showed ileocecal
mesenteric lymphadenitis and dilated intestinal loops filled with
dense liquid content. Upon the first examination by paediatric
rheumatologist he had palpatory periumbilical pain as well as tender-
ness of SI joints and Achiles entheses. His height and weight were
below the 5th centile while estimated bone age was 12. ANA, ANCA
and RF were negative. There was no sign of uveitis on ophthalmo-
logic examination. HLA typing was positive for B27. Radiographic and
magnetic resonance imaging of SI joints and spine showed no signs
of inflammation. Immunoglobulin A anti-tissue transglutaminase anti-
body (IgA TTG) was negative while serum IgA levels were normal. No
pathological agents were isolated from stool. Several faecal occult
blood tests were negative and faecal calprotectin levels were normal.
Endoscopy of upper and lower gastrointestinal tract revealed hiatal
hernia, oesophagitis, gastritis and duodenitis. Histologic evaluation of
several duodenal biopsy specimens displayed typical features of ce-
liac disease. A month after initiation of gluten free diet and NSAID’s
the improvement of all symptoms was noticed.
Conclusion: although they differ in HLA predispositions, both JIA and
CD are associated with 4q27 locus, which encodes IL-2 and IL-12 cy-
tokines important for activation and regulation of immune system,
and both are linked with a functional single nucleotide polymorph-
ism in the PTPN22 gene (1858C > T). Intriguingly, lymphocyte cyto-
toxicity in the intestinal mucosa is abnormally increased in both
entities, suggesting some luminal, possibly a nutritional factor, may
be involved. This agent is well established in CD, but number of
cases, including presented, exhibited beneficial role of gluten free
diet in arthritis patients as well. Our patient clearly met ILAR criteria
for ErA and had typical histological features of CD, but without ele-
vated anti-TTG levels. Since his musculoskeletal symptoms could also
be explained as a part of extra-intestinal CD manifestations, the real
distinction of underlying disorders was challenging. Therefore it is
reasonable to conclude both CD and certain subtypes of JIA have
Pediatric Rheumatology 2017, 15(Suppl 2):59 Page 185 of 191multiple shared mechanisms making them hard to separate in given
circumstances.
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Introduction: New immunomodulatory therapies that have emerged
over the past years have greatly improved success in autoimmune
disease treatment. We present a case of refractory systemic JIA (sJIA)
that despite extended medical treatment shows activity of the
disease.
Objectives: As this case with exhausted use of new immunomodula-
tory drugs illustrates the limitation of therapeutic options available
for sJIA it shows on the other side a good safety profile without se-
vere side effects.
Methods: Case Report
Results: An eleven year old girl presented with typical signs of sJIA
with recurring fever over 2 weeks, typical rash, and splenomegaly.
After stopping the oral steroids reactivation of the disease with
gonarthritis and fever occurred both under the treatment with NSAID
(Naproxen) and Methotrexate (MTX) injections (17.5 mg/week). Even
the intravenous therapy with Tocilizumab (8 mg/kg every 2 weeks)
and steroids didn’t show any sufficient effect as fever, rash and arth-
ritis persisted. A first attempt with Canakinumab (150 mg) failed be-
cause of high fever and arthritis 10 days after the first injection,
which was continuing after the premature second injection after
24 days already. As a next step we installed Anakinra with an initial
dose of 40 mg/day (1 mg/kg/day).The dose needed to be raised be-
cause of signs of systemic inflammation and after an intravenous
steroid pulse treatment we reached temporary stability at the dosage
of 100 mg daily (2.4 mg/kg/day) still under high dosage of steroids
(60 mg daily). An exacerbation presenting as MAS with rapidly raise
of ferritin to 5850ug/l along with other activity values caused an add-
itional therapy with Cyclosporine and the elevation of Anakinra to
200 mg daily (4.7 mg/kg/d) after treatment of MAS with intravenous
steroid pulse therapy. Under this treatment a stabilization of her con-
dition was seen including disappearance of fever and normalization
of the laboratory values. Gradually we could taper the oral steroids
over 8 month from 60 mg daily to 10 mg daily, but under the dosage
of 10 mg (0.23 mg/kg/d) signs of systemic inflammation returned. As
an immunomodulatory effect as well as to prevent septic complica-
tions due to long lasting treatment with steroids we started intraven-
ous immunoglobulin (0.4 g/kg) monthly and Posaconazol as
antifungal prophylaxis. While again rising the steroid doses up to
60 mg/day and briefly to 80 mg/d our patient still presented with
intermitting fever and high activity signs in the lab. This brought us
to change again the IL-1-antagonist to Canakinumab after about one
year of therapy with Anakinra that in fact also caused strong local re-
action due to the injections that were applied twice daily. During
11 month of therapy with Canakinumab, gradually raised from
300 mg/3 weeks to 300 mg/2 weeks, we had at least for a short time
a satisfactory response with low lab activity and no fever under
60 mg/d Prednisolon and 300 mg/2 weeks Canakinumab. But the at-
tempt to reduce the steroid therapy failed again. At a dose of oral
steroids of 50 mg/day persisting fever with signs of inflammation in
the lab occurred.
At least in contrast to prior therapeutic setting with this extended
treatment (fourfold dose of Canakinumab, high-dose of oral steroids,
intravenous immunoglobulin monthly, additionally Cyclosporine and
MTX) the only clinical symptom was fever. Some lab values (LDH,
AST, ALT, CRP, ESR) showed little activity, but no rush, no arthritisand no signs of MAS were seen as a partial respond to this treatment.
For all that high immunosuppressive therapy we did not have any
severe infections nor other serious side effects beside short stature and
the cataract due to the long lasting steroid therapy.
Conclusion: This exemplary case illustrates the still ongoing three-
year search for effective therapy in a patient with sJIA, the whole
spectrum of current therapeutic possibilities and its safety profile con-
cerning severe infections. It also shows us that even with new immuno-
modulatory therapies there are still limitations in controlling the disease.
Disclosure of Interest
None Declared
Systemic lupus erythematosus and
antiphospholipid syndrome
B20
Growth in children with Juvenile Systemic Lupus erythematosus in
the Sultanate of Oman
Eiman Abdalla1, Irfan Ullah1, L Jeyaseelan2, Reem Abdwani1
1Child health, Sultan Qaboos University Hospital, Muscat, Oman;
2Biostatistics, Sultan Qaboos University Hospital, Muscat, Oman
Correspondence: Eiman Abdalla
Pediatric Rheumatology 2017, 15(Suppl 2):B20
Introduction: Systemic lupus erythematosus (SLE) is a chronic, multi-
system autoimmune disease with juvenile onset SLE representing 10-
20% of all SLE cases and with earlier diagnosis and better ap-
proaches to treatment, there has been marked improvement in the
prognosis but with more morbidities seen, such as growth failure
and pubertal delay.
Objectives: The goal of our study is to assess growth of Omani chil-
dren with juvenile onset SLE, by evaluating their anthropometric
measurements, identifying growth failure and study contributing fac-
tors to growth failure.
Methods: This is a retrospective study in which the serial anthropo-
metric measurements (weights and heights) of patients with juvenile
onset systemic lupus erythematosus (jSLE) following in pediatric
rheumatology, child health department in SQUH are retrieved from
their records. Inclusion criteria include children below 16 yrs. of age
who are diagnosed with jSLE as per 1982 revised ACR criteria. An-
thropometric measurements are obtained at disease onset, 6 months,
12 months and 24 months after disease onset. Parents’ heights are
measured to calculate the child’s respective sex-adjusted mid paren-
tal height (target height). This is calculated by adding 2.5 inches or
6.5 cm to the mean of the parents’ heights for boys while for girls,
subtract 2.5 inches or 6.5 cm from the mean of the parents’ heights.
Parent-adjusted height z score is calculated as the difference be-
tween height z score for chronological age and target height. Growth
failure was defined as parent-adjusted height z score less than −1.5.
Height deflection (decreased height z score > − 0.25 per year) com-
pared to baseline was evaluated. Factors which might have attrib-
uted to growth failure were studied and these included growth
failure at baseline, disease duration, disease activity (SLEDAI score)
and cumulative steroid dose.
Results: Twenty five out of 31 patients have complete data (6 patients
could not get either of parents height as only one parent come with
patient, 2 patients are no longer following with us). Growth failure is
identified in 8 patients (female: male ratio of 7:1) hence the hospital
prevalence and the 95% CI of growth failure is 32% (13.7%, 50.2%) in
our study. The female prevalence of growth failure is 35% as compared
to male prevalence 20%. However, the difference was not statistically
significant (p value 0.915). Growth failure determinants were previous
growth failure at initial assessment (p 0.00) and high cumulative cor-
ticosteroid doses (p 0.061), while disease duration and disease activity
were not found to be statistically significant contributing factors (p
value 0.24 and 0.52, respectively).
Conclusion: Growth failure was identified in our children with juven-
ile SLE, and those at risk were those who already had growth failure
previously and those who received high corticosteroid dose.
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Introduction: SLE s an autoimmune disease that affect women pri-
marily of childbearing age. As a consequence, pregnancy and its neo-
natal outcome are of particular importance in this condition. It
appears that individual races and ethnicities may exhibit differences
in disease susceptibility and disease manifestations. There are limited
studies in SLE patients emanating from Arab world, however, it is
recognized that Arabs experience a different disease burden than
Caucasians
Objectives: To determine differences in maternal and neonatal out-
comes in pregnancies complicated with systemic lupus erythemato-
sus (SLE) compared to those with normal pregnancies in Arab
women from Sultanate of Oman.
Methods: A retrospective analysis of 147 pregnant mothers with
their corresponding infants was enlisted (56 (38%) SLE mothers and
91 (62%) pregnant controls). Analyses were performed using descrip-
tive statistics.
Results: The overall mean age of the cohort was 30 ± 5 years ran-
ging from 19 to 44 years. The SLE mothers were mainly treated
with hydroxychloroquin (n = 41; 73%), prednisolone (n = 38; 68%)
and azathioprine (n = 17; 30%). Disease activity revealed that 39%
(n = 22) had no disease activity while 41% (n = 23), 13% (n = 7)
and 7.1% (n = 4) had mild (SLEDAI, 1–5), moderate (SLEDAI, 6–10)
and severe (SLEDAI, 311), respectively. The SLE mothers were as-
sociated more with abortions (43% vs. 15%; p < 0.001), gestational
diabetes (28% vs. 10%; p = 0.004), polyhydramnious (7.1% vs. 0; p
= 0.020), pre-term labor (21% vs. 1.1%; p < 0.001), previous pre-
term (8.9% vs. 1.1%; p = 0.030) and intra-uterine growth retard-
ation (21% vs. 0; p < 0.001) when compared to normal pregnant
controls. Furthermore, the neonates born to SLE mothers were
more likely to be pre-term (29% vs. 1.1%; p < 0.001), had low
birth weight (<2500 g) (32% vs. 1.1%; p < 0.001) and associated
with still birth (7.1% vs. 0; p = 0.010) when compared to neonates
born to normal pregnancies (Table 2).
Conclusion: SLE mothers were associated with worse neonatal
and maternal outcomes when compared to normal pregnant
mothers despite adequate disease control and antenatal follow
up.
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Characteristic,
n (%) unless specified otherwise
All
(N = 147)
Non-SLE (n = 91) SLE
(n = 56)
P-value
Age, mean ± SD, years 30 ± 5 29 ± 5 31 ± 5 0.145
Primigravida (1) 35 (24%) 24 (26%) 11 (20%)
Multigravida (2–4) 79 (54%) 52 (57%) 27 (48%) 0.084
Grand multigravida (>5) 33 (24%) 15 (16%) 18 (32%)
Abortions 38 (26%) 14 (15%) 24 (43%) <0.001
Gestational diabetes 24 (17%) 9 (10%) 15 (28%) 0.004
Polyhydramnios 4 (2.7%) 0 4 (7.1%) 0.020
Pre-term labour 13 (8.8%) 1 (1.1%) 12 (21%) <0.001
IUGR 12 (8.2%) 0 12 (21%) <0.001B22
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Introduction: Hepatic involvement in patients with SLE is well docu-
mented, but considered to be rare. To distinguish whether elevated
liver enzymes in patients with SLE represent a non-specific hepatic
involvement or AIH remains a difficult challenge for the treating
physician.
Objectives: We present the case of a 17,5 years old girl with Juvenile
Systemic Lupus Erythematosus initially diagnosed as autoimmune
hepatitis.
Methods: A 15,5 years old girl with the diagnosis of autoimmune
hepatitis presented to our department two years ago seeking a sec-
ond opinion. Laboratory exams done due to a persistent maculopap-
ular rash of hands, elbows and feets (considered initially as contact
dermatitis) had revealed a significant increase of transaminase levels
(4fold above the upper normal limit). Gamma glutamyl transpepti-
dase, rheumatoid factor IgM and immunoglobulin G were also ele-
vated. A more extensive laboratory work up excluded viral hepatitis
A,B and C, Wilson disease and celiac disease. Serological work up re-
vealed positive antinuclear (ANA), smooth muscles antibodies (SMA)
and anti liver cytosol type 1 (anti –LC-1) antibodies.IgM antibodies
against Coxsackie virus, ECHO virus and Epstein Barr virus were also
positive. Liver biopsy was performed and revealed no pathology.
Based on serological markers the diagnosis of AIH was considered as
most probable and the girl was started on per os prednisolone ther-
apy (0,5 mg/kg).
Results: On physical examination the girl had reticular peliosis, arthritis
of metatarsophalangeal joints and a papular rash of hands, elbows and
feet with no clinical sign of chronic liver disease (jaundice,firm liver,he-
pato/spleno megaly,palmar erythema).Based on normal liver histology
we considered the diagnosis of autoimmune hepatitis as less probable.
Supplemental laboratory exams revealed low complement C3 and posi-
tive anti Ro antibodies and Coombs test.Cardiological examination
showed a small pericardial effusion. SLE was diagnosed and hydroxy-
chloquine was added to treatment. Nine months later,while receiving a
low dose of steroids,she developed a typical malar rash and nephritis
with significant proteinuria and hypoalbuminemia. A renal biopsy
showed early membranous nephritis. Treatment with pulses of methyl-
prednisolone (3 pulses on 3 consecutive days,1gr each), followed by
per os steroids and azathioprine were started leading to a complete
resolution of malar rash, cutaneous eruptions and proteinuria.Steroids
were slowly tapered. The girl is now treated with hydroxychloquine,a-
zathioprine (2,5 mg/kg) and a low dose of prednisolone (5 mg/day).SLE
activity remains low (SLEDAI 2 K:2).
Conclusion: Specific markers for AIH are soluble liver antigen (SLA),
liver-pancreas, smooth-muscle antibody (SMA) with specificity for F-
actin and microsomal autoantigens, such as anti-liver kidney anti-
bodies (anti-LKM antibody). While these markers may help to differ-
entiate AIH from SLE serologically, liver histopathology represents
the key feature that distinguishes AIH in SLE from nonspecific hep-
atic involvement in SLE. In patients with AIH liver histopathology
shows characteristic lesions, such as interface hepatitis, rosetting of
hepatocytes, emperipolesis and - consecutive to inflammation - fibro-
sis. As the diagnosis of AIH in SLE patients can influence treatment
choices, longterm outcome and optimal surveillance of the patients,
adequate attention should be taken to differentiate between “true
additional” AIH and secondary liver involvement.
Disclosure of Interest
None Declared
Pediatric Rheumatology 2017, 15(Suppl 2):59 Page 187 of 191B23
Pyrexia of Unkown Origin (PUO) and severe ventricular systolic
dysfunction – presenting manifestations of childhood SLE in a
15 year old boy
Mahesh Janarthanan1, Dhanarathnamoorthy Vetrichelvan2, P
Ramachandran2, Sangeetha Geminiganesan2, Dinesh Kumar2, Subba
Rao2
1Division of Pediatric Reumatology, Sri Ramachandra University, Chennai,
India; 2Department of Pediatrics, Sri Ramachandra University, Chennai,
India
Correspondence: Mahesh Janarthanan
Pediatric Rheumatology 2017, 15(Suppl 2):B23
Introduction: Cardiac manifestations in childhood SLE are not un-
common. Up to 50% of patients can have cardiac manifestations in-
cluding pericarditis, pericardial effusion or valvular vegetations.A
significant proportion of these patients do not have cardiac related
symptoms and these manifestations are picked up on screening by
echocardiogram.
Objectives: Severe ventricular systolic dysfunction is very rare as a
presenting manifestation in childhood SLE.
Methods: We present the case of a 15 year old boy with childhood
SLE who presented to us with pyrexia of unknown origin and severe
ventricular systolic dysfunction needing immune modulators,inotro-
pic and ventilator support.
Results: A 15 year old boy presented with history of fever for 15 days
and 2 episodes of generalized tonic,clonic seizures. He did not have
any other features suggestive of connective tissue disorder.His inves-
tigations on admission revealed Hb-10.9gms/dl, Total white cell
count- 5400cells/cumm, Polymorphs 79%, Lymphocytes −15.9%,
Platelet count 122000,ESR – 71 mm/hr. Direct Coomb’s test was
negative.His liver function tests showed transaminitis SGOT 442U/l
and SGPT 131 U/l. Serum uric acid 8.6 mg/dl and serum LDH 2387 U/
l were elevated. Serum creatinine was 1 mg/dl and urine routine
showed 1+ proteinuria with few red blood cells. Bone marrow exam-
ination revealed reactive changes.
Cerebro spinal fluid analysis and MRI brain were normal. He was
commenced on empirical antibiotics and antiviral agents. On day 3
of admission to hospital he developed breathing difficulty with drop-
ping of blood pressure. Chest Xray showed cardiomegaly.Echocardio-
gram at this stage revealed severe left ventricular dysfunction with
an ejection fraction of 20% and mild pericardial effusion. He was
treated with ventilatory and inotropic support.The results of his auto-
immune work were now available and this revealed ANA positive
1:320 and low complement levels. dsDNA, ENA and APLA work up
were negative.
He was treated with dobutamine, milrinone,spirinolactone and fur-
osemide infusion. He also received pulsed methylprednsiolone, IVIG
and cyclophosphamide.The patients hemodynamic status improved
gradually and he was weaned off inotropic and ventilatory support
over 2 weeks. After he stabilized a renal biopsy was done and this re-
vealed class III lupus nephritis. The patient is currently on a maintai-
nence regimen with low dose steroids, hydroxychloroquine,
mycophenolate mofetil and enalapril.
Conclusion: Severe ventricular dysfunction with very low ejection
fraction as presenting cardiac manifestation of SLE has rarely been
reported in childhood SLE. Combination of supportive measures,
pulsed high dose methylprednisolone, IVIG and cyclophosphamide
was life saving in this patient.
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Pediatric Rheumatology 2017, 15(Suppl 2):B24Introduction: Systemic Lupus Erythematosus (SLE) is the prototype
of autoimmune diseases which affects mostly women of childbearing
age. It is estimated that for 15-20% of all patients, the onset of the
disease is in childhood. Recent evidence suggests that genetic
factors transmitted by the X-chromosome may confer increased risk
for SLE and autoimmunity in general. The calculated prevalence of
SLE in females with triple X syndrome (47, XXX), which accounts for
1 in 1000 births, is three times higher than in 46XX females. It is also
known that SLE is more common in males with Kleinfelter syndrome
(47, XXY) rather than in genotypic 46XY.
Objectives: We present a patient with mosaic 47ΧΧΧ (90%) and 46ΧΧ
(10%) who was diagnosed with SLE
Methods: Case report
Results: A 13-year old girl presented to our hospital with pain and
swelling of her right hand and her left foot, asthenia, headaches,
mouth sores and a rash on her legs. Symptoms initiated 3 weeks
prior to admission. Prenatal screening had shown a mosaic embryo
with two cell lines 47, XXX (90%) and 46, XX (10%).
On examination she had arthritis of her right wrist and left ankle
joints, a diffuse purpuric rash primarily affecting her lower limbs, fa-
cial erythema and mouth ulcers. Examination of her cardiovascular,
respiratory, gastrointestinal and central nervous systems was intact.
There was no lymphadenopathy. On admission, laboratory tests re-
vealed marginal leucopenia (WBC 4000(N 50.8%/L 41.1%/M 6%),
Coombs positive hemolytic anemia, (Hb 9.7 g/dl) and an ESR of
40 mm/h. Renal function tests showed urea of 53 mg/dl (nv 5–44)
and creatinine 0,9 mg/dl (nv 0.4-0.8). Moreover, antinuclear antibody
titer >1/640, diffuse, positive mitotic pattern, anti-dsDNA positive
(RIA >90), low complement levels C3 43.8 mg/dl C4 4.26, CH50 < 10,
anti ENA positive, anti SSA (Ro) positive. Urinanalysis showed severe
proteinuria and hematuria, in keeping with active nephritis. The re-
sult of the renal biopsy was diffuse proliferative glomerulonephritis
with individual membranoproliferative ‘standard’, findings consistent
with SLE nephritis IV-G class (A). During her hospitalization her vital
signs remained stable.
Her medical management included methylprednisolone pulses
followed by slow corticosteroid tapering, mycophenolate mofetil and
hydroxychloroquine.She adequately responded to treatment and is
on a regular follow up.
Conclusion: For years SLE female predilection was considered as a
hormonal hypothesis. Recent data on epigenetic X-chromosome non
deletion on somatic female cells support the phenomenon of gene
overexpression on X-chromosomes as responsible for female predis-
position. X-polysomy with its abundance of X-chromosomes may rep-
resent a nature’s experiment on the effect of gene dosage on the
expression and pathogenesis of SLE. Thus, X-polysomy should highly
suspected for SLE.
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Introduction: Canakinumab is a human monoclonal anti-IL-1β anti-
body that neutralizes the activity of IL-1β by binding to it. Canakinu-
mab is used effectively in many of the AIDs.
Objectives: The aim of this study is to demonstrate diagnosis, demo-
graphic features, indications, and response rates of the patients that
have used canakinumab.
Methods: This study was conducted in pediatric rheumatology clinic
of Istanbul Kanuni Sultan Süleyman Research and Training Hospital.
Pediatric Rheumatology 2017, 15(Suppl 2):59 Page 188 of 191The files of the patients that canakinumab have been used between
December 2012 and January 2017 were reviewed.
Results: Canakinumab was used in 23 patients. Diagnosis of the pa-
tients were; colchicine resistant (cr) FMF (15 cases), HIDS (2 cases),
CAPS (2 FCAS cases and 1 CINCA case), sJIA (2 cases), and pyoderma
gangrenosum (1 case). Canakinumab has been used for 24.8 months.
Canakinumab was discontinued in 3 patients. In crFMF patients, the
reason for use of biologic agent was resistance to colchicine that was
described as having ≥3 attacks for 6 consecutive months despite
maximal colchicine dose in this study. The crFMF patients had a strik-
ing female predominance; 13 girls and 2 boys. Mean age at the initial
symptoms of FMF was 2.6 years. Twelve patients had M694V homozy-
gous mutation, 1 patient had M694V/R761H compound heterozygous
mutation and in 2 of the cases we could not have demonstrated a
pathogenic mutation in the MEFV and other AID gene studies. In 10 of
15 crFMF patients, anakinra was used before canakinumab for
6.7 months. Mean number of attacks per year before colchicine was 18,
after colchicine it was 6.8 and after biologic agent the number dropped
to 0.7. At the time of enrollment, in 6 patients canakinumab was being
used every month and in 8 patients every 3–4 months. Acute phase re-
actants regressed dramatically; CRP from 151.2 mg/L to 1 mg/L, SAA
from 442.6 mg/L to 2.2 mg/L, ESR from 48 mm/h to 7 mm/h. Two of
the HIDS cases of this cohort were siblings. Both had V377I mutation in
the MVK gene. Anakinra was used for 9 months before canakinumab
and canakinumab was being used for 3 months with resolution of the
attacks. Two FCAS patients were using canakinumab for 5 and 9 months
with total disappearance of rash. CINCA patient did not show dramatic
response to IL-1 blockers with partial control of the acute phase reac-
tants. Canakinumab 12 mg/kg/month with low dose prednisolone were
used and laboratory and clinical parameters are under control. In one
of the sJIA patients canakinumab was being used for 21 months with
good response. But other sJIA case initially followed a polycyclic course
and for 28 months canakinumab was used with a good response but
later turned into polyarticular course under canakinumab treatment. A
severe pyoderma gangrenosum patient had failed dapson and ana-
kinra, and failed also canakinumab that is used for 9 months. We did
not observe any side effect under canakinumab treatment.
Conclusion: In conclusion, canakinumab seem to be effective and
safe in patients with AIDs.
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Introduction: Juvenile idiopathic arthritis (JIA) is the most common
rheumatic disease in children and it is characterized by a primary le-
sion of the joints, organs and tissues with the formation of multiple
organ failure of varying severity.
Objectives: The article describes the results of studying the efficacy
and safety of adalimumab in combination with methotrexate (n = 14)
and methotrexate monotherapy (n = 17) when treating the patients
with polyarticular JIA refractory to the basic immunosuppressive
therapy.
Methods: Retrospective analisis of 31 patient with JIA
Results: It was shown that the combination therapy induced the re-
mission of arthritis in children with JIA in a shorter period of time. It
should be noted that adalimumab in combination with methotrexate
was well. tolerated and no serious adverse effects were recorded.
Thus, the introduction of adalimumab in the treatment regimen of
children with JIA refractory to the basic immunosuppressive therapyallowed for the rapid disease remission while preserving the effect in
a significant number of patients during the following year.
Conclusion: Definition levels cytokins in blood and synovial fluids ap-
pears important investigation for diagnostic and effective therapy Ju-
venile Idiopathic Arthritis in patients.
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Introduction: JIA is a broad term that describes a clinically heteroge-
neous group of arthritis of unknown cause. Although none of the
curative drug has been developed, the most important new drug has
been introduced such as biologic products. Management of JIA is
based on a combination therapy with MTX/etanercept recently.
Objectives: The aim of this study was to investigate efficacy of eta-
nercept in JIA and to find out the difference efficacy of JIA subtypes.
And the second aim is to announce the our results to the
pediatrician who take care of JIA patients. Because there is few
pediatric rheumatologist in Korea.
Methods: JIA patients (n = 53) who have been treated with etaner-
cept during the 2010 through 2016 were chart reviewed retrospect-
ively. Systemic JIA (n = 11). poly JIA (n = 16). extended olioarthritis (n
= 25). ERA (n = 1). Mean age was 9 years (4-17years) and the sex ratio
was 25:28 (boy : girl). We compaired the swollen joints and inflam-
matory markers every 3 months.
Results: The mean value of ESR and CRP were decreased within
3 months. Also the mean swollen joints were significantly de-
creased within 3 months. The adverse events were new onset or
recurrent uveitis (n = 2). All of these two patients were switched
to adalimumab.
Conclusion: The remarkable and rapid efficacy and the good safety
profile of the etanercept. AntiTNF agents in children are usually well
tolerated. RF (−) polyarticular JIA patients has best outcomes com-
pared with other types. Systemic JIA have significantly improved, but
mean value of ESR and CRP dose not normalized until 15 months.
The pathophysiology of systemic JIA maybe different from that of
other subtypes of JIA. However, physicians should remain alert for
potential side-effects, especially reactivated tuberculosis during treat-
ment with TNF inhibitors. All children should have a documented
negative tuberculosis test before any biological therapy is started.
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Pediatric Rheumatology 2017, 15(Suppl 2):59 Page 189 of 191Introduction: Pneumonia is a possible associated radiological found-
ing in Kawasaki disease (KD). However clinical impact is mild and the
relieve is occasional, by chest radiogram. In a large series of chest ra-
diograms in children with KD, about 15% of the patients had patho-
logical pictures, mainly interstitial lung changes.
Objectives: Reports in the international literature on lung consolida-
tion as part of KD or as the presenting symptom of KD are rare. Only
a few cases of severe pneumonia in children affected by KD are
reported.
Methods: A 2-year-old male was admitted to our unit with the pres-
ence of 5 days of fever, diffuse maculopapular eruption, conjunctiv-
itis, lips cracking and erythema, bilateral conjunctivitis, oedema of
hands and feet, cervical lymphadenopathy.
Results: He showed: CRP 16.24 mg/dl,, Hb 11.1, WBC count 23.790
(N: 65.5%), platelets 383.000, mild sterile pyuria. Echocardiography
performed on the fifth day of the disease revealed the absence of
coronary anomalies. The diagnosis was “typical KD” and he received
IVIG (2 gr/kg) with ASA (50 mg/kg/day).
The child had been afebrile and showed reduction without complete
resolution of the rash. A blood sample showed a significant reduction
of CRP (6.09) and WBC (7.590; N: 37.4%): hence reduced the ASA
dose was reduced. However fever started again 3 days later, in asso-
ciation with rash and conjunctivitis.
Blood sample evidenced: CRP: 9.08; WBC 16.850 (N: 69%); platelet:
731.000; Na: 131; albumin: 3.2. He received a second dose of IVIG
with resolution of fever, rash, conjunctivitis. ECG and echocardiog-
raphy were still normal.
For the unexpected course of the disease, the chest radiographs
were performed and revealed consolidation in the right middle lobe
and opacity of the pulmonary hilum. TC confirmed a lung consolida-
tion with pleural effusion. There were no respiratory symptoms or
signs, and the respiratory rate, lung auscultation and oxygen satur-
ation were normal.
He was treated with several antibiotics, including clarithromycin, cef-
triaxone, chloramphenicol, imipenem and teicoplanin.
Quantiferon, bronchoalveolar lavage with culture and PCR were
negative, excluding an infectious agent. 7 days later, ASA was re-
duced to the dose of 5 mg/kg, however fever restarted 48 hours
later. The clinical worsening was associated with the following pa-
rameters: CRP: 10.24; WBC 14.100 (N: 69%); platelet: 815.000. Chest
ray evidenced a reduction of the pneumonia. The patient started
methylprednisolone (2 mg/kg/day), associated with ASA (5 mg/kg/
day). The clinical course showed the resolution of fever and the pro-
gressive normalization of CRP in 7 days. Chest ray and CT showed a
progressive resolution of pneumonia. The tapering of methylprednis-
olone till the suspension and the resolution of the clinical signs was
not associated with CAL.
Conclusion: Typical KD in pediatric patients can present with atypical
manifestations that could make difficult the follow-up and create
doubt in initial diagnosis, especially in non-responder patients. The
clinical presentation of the child was uncommon. In fact he initially
presented a complete KD however, when he had the relapses, the
disease showed an unresolving pneumonia as the main manifest-
ation of atypical KD.
In literature, the association of KD with unresolving pneumonia is
rarely described: this case, however, showed a singular course: Kawa-
saki disease started as a “typical” form and the failure of IVIG treat-
ment was linked to a complicated pneumonia. The pneumonia did
not reveal an infectious aetiology and the child required steroids to
resolve the disease. The real aetiology of pneumonia can explain the
favourable course of the disease, after steroids were started. In conclu-
sion, Atypical KD should be considered in the differential diagnosis of
children with persistent fever and lobar consolidation unresponsive to
antibiotics.
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Introduction: Childhood polyarteritis nodosa (PAN) is a rare systemic
inflammatory disease characterized by systemic necrotizing vasculitis
of the small or medium sized arteries that leads to infarct, and aneu-
rysms in various organs.
Objectives: We wish to share our experience of systemic polyartertis
nodosa.
Methods: Case presentation
Results: A 7 year-old girl was admitted due to sudden onset of
painful blackish discoloration of right 2nd, 4th and left 2nd finger
tips from proximal interphalangeal joints with fever. She could
not walk by herself because of myalgia on both lower extremities.
On admission, body temperature was 38.5 °C, and blood pressure
150/86. Physical examination showed gangrenous change of fin-
ger tips and tender swelling on right ankle joints. Initial laboratory
data showed leukocytosis with dominant neutrophils, high C-
reactive protein and ESR. Autoantibodies including ANA and
ANCA showed negative. We identified microscopic hematuria. CT
angiography for upper and lower extremities showed diffuse
swelling with soft tissue fatty infiltration on both fingers, but no
definite vessel and its branch abnormalities and renal arteries.
Brain MRA showed luminal irregularity at intracranial major arter-
ies compatible with arteritis, but no definite aneurysm. Electro-
myographic findings for motor showed decreased amplitudes in
right median and ulnar nerves. Skin biopsy showed perivascular
lymphohistiocytic infiltration compatible with vasculitis without
any immunofluorescent staining. Culture for skin, blood, and urine
was no any organisms. We diagnosed with systemic PAN includ-
ing skin change, arthralgia and myalgia, hematuria, histologic
findings and neuropathy. We started with low molecular weight
heparin, prostaglandin E for prevention of thrombisis, and mor-
phin for pain control. She received intravenous immunoglobulin
and intravenous steroid. She was improved symptoms after ster-
oid therapy, but still no changes of digital gangrene. We changed
anti-coagulation therapy to Warfarin. She was tolerable after oral
steroid and warfarin.
Conclusion: We present a girl with systemic polyarteritis nodosa as
initial manifestation of digital gangrene.
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Pediatric Rheumatology 2017, 15(Suppl 2):59 Page 190 of 191Introduction: Kawasaki disease (KD) is an acute systemic vasculitis
of unknown etiology affecting most often children younger than
5 years of age and characterized by high fever, bilateral conjunc-
tival hyperemia, mucosal changes of the oropharynx, erythemato-
sus rash, erythema and indurative edema of the hands and feet,
and cervical lymphadenopathy. Approximately 20–25% of un-
treated patients develop coronary artery changes with a range of
severity from asymptomatic coronary artery dilatation or aneu-
rysms to giant coronary artery aneurysms with thrombosis, myo-
cardial infarction and sudden death. To date there is no official
data on the incidence of KD in Russia. In Russia the disease to
date is not enough known to a wider circle of doctors and often
goes under the “mask” of other more common diseases. In Saint-
Petersburg since 2010 has dramatically increased the recognition
rate of KD.
Objectives: to review the experience of diagnosis and treatment of
KD in the two largest hospitals in St. Petersburg.
Methods: the retrospective study included data on 30 children
(18 boys, 12 girls) who were hospitalized with a diagnosis of KD
in the clinics of Saint-Petersburg State Pediatric Medical Univer-
sity and Children’s Hospital No. 1 (St. Petersburg) from January
2011 to September 2016. Data is represented by the median and
extreme ranges.
Results: the age of the children was 2,8 years (0,2; 4,6), 5 patients
(16,7%) were under the age of 1 year. The children were hospital-
ized on the 5th days of illness (1; 14 days), the diagnosis of KD
was established on the 9th day of the disease (3; 52). Immediately
after diagnosis aspirin have got 27 children (90%). In the early
stages (before 10 days of illness), therapy with intravenous im-
munoglobulin has received 15 children (50%), 1 of them received
intravenous immunoglobulin before 5 days of illness (on day 3)
and has not responded to the treatment. On 11–20 day (immedi-
ately after diagnosis) treatment with intravenous immunoglobulin
received 10 children (33,3%), after which the fever decreased in
all patients. Fever was stopped on day 11 (6; 23). Lesions in cor-
onary arteries by ultrasound were diagnosed in 13 children
(43,3%). The youngest patient who became ill at the age of
3 months and received intravenous immunoglobulin on the 30th
day of illness dead.
Conclusion: KD should always be included in the differential
diagnosis in children of early age with prolonged fever, espe-
cially in children of the first year of life, which is often ob-
served incomplete forms of KD. It is necessary to increase
awareness among clinicians and doctors of ultrasonic diagnos-
tics about KD.
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Introduction: Takayasu arteritis is rare idiopathic chronic granuloma-
tous inflammatory disease of the large vessels that involves the aorta
or its branches and the pulmonary arteries.Objectives: EULAR/PRINTO/PRES Ankara 2008 classification of child-
hood Takayasu arteritis requires angiographic abnormalities of the
aorta or its main branches and pulmonary arteries showing
aneurysm/dilatation (mandatory criterion) plus one of the five follow-
ing criteria: Pulse deficit or claudication, four limbs BP discrepancy,
bruits, hypertension and elevated acute phase reactant. In childhood
Takayasu arteritis the thoracic and abdominal aorta are the most
commonly involved vessels.
Methods: We describe the case of an 8 year old girl with
Takayasu arteritis presenting with isolated pulmonary artery
involvement.
Results: An 8 year old previously well girl presented with pyrexia
of unknown origin of one month duration. She was initially eval-
uated at another centre where a routine chest X-Ray revealed di-
lated pulmonary vessels and patchy opacities in superior and
lateral segments of right lower lobe and lingual. Though investi-
gations were negative for tuberculosis she was started on empir-
ical antituberculous therapy. In view of persistent fever, new
onset cough and exertional dyspnoea she was referred to our
centre.
On examination she had grade 2 clubbing, periorbital puffiness,
elevated jugular venous pulse, loud second heart sound. Her 4
limb blood pressure readings were normal and there was no
hypoxia.
Laboratory investigations showed anemia(9.3gms/dL), elevated in-
flammatory markers(CRP: 120 mg/L; ESR: 80 mm/hr). Chest x- ray
showed marginal cardiomegaly with prominent pulmonary arter-
ies. ECHO showed severe pulmonary hypertension and right ven-
tricular dysfunction. cANCA was weakly positive and pANCA was
negative. MRA chest and abdomen showed dilated main, right
and left pulmonary arteries and focal thickening with narrowing
in the distal right and left pulmonary arteries with dilatation of
lobar pulmonary arteries. The thoracic and abdominal aorta were
normal.Clinical history, laboratory parameters and imaging were
suggestive of Takayasu arteritis with isolated pulmonary arterial
involvement.
She was commenced on diltiazem and sildenafil for pulmonary
hypertension. For the vasculitis she was treated with steroids, low
dose aspirin and monthly cyclophosphamide.
Conclusion: Involvement of pulmonary arteries is common in
Takayasu arteritis. Isolated pulmonary arteritis though rare, is re-
ported in adult Takayasu disease. To our knowledge this is the
youngest patient to present with isolated pulmonary artery
involvement.
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Introduction: Takayasu arteritis (TA) is a chronic granulomatous
large vessels panarteritis predominantly affecting the aorta
Pediatric Rheumatology 2017, 15(Suppl 2):59 Page 191 of 191and its major branches. The diagnosis and treatment of child-
hood TA remains a challenge due to (1) differences in clinical
spectrum compared to adult TA, (2) the invasive nature and
radiation exposure of conventional angiography and (3) the
paucity of available data regarding treatment options in child-
hood TA.
Objectives: The aim of this case report was to describe a single-
center pediatric case of TA presenting with heart failure as the
main disease manifestation and review four such cases reported
in the literature.
Methods: PubMed, MEDLINE and Google Scholar were screened
using the following key words: “Takayasu”, “Takayasu arteritis”,
“heart failure”, “cardiomyopathy”, “dilated cardiomyopathy”. After
applying age, language, article type and text availability filters,
four articles were included in this literature review. Several pa-
rameters were analyzed: age at diagnosis, gender, left ventricular
ejection fraction (LVEF) on echocardiography, vascular imaging
techniques, glucocorticoid regime, immunosuppressive agents,
biological therapy, surgical interventions, angioplasty and re-
sponse to medical or surgical treatment.
Results: A 14-year-old girl presented with signs and symptoms
of acute heart failure. Past medical history revealed progressive
dyspnea on exertion, cough and claudication of the lower limbs
during the past year. She was repeatedly treated with antibi-
otics for community-acquired pneumonia. Physical examination
showed high, discordant blood pressure in the upper limbs
(right arm 190/110 mmHg, left arm 150/80 mmHg), no periph-
eral arterial pulses in the lower and left upper limbs, basal
crackles in both lungs, hepatosplenomegaly and lower limb
edema. Ecocardiography and cardiac magnetic resonance identi-
fied severe left ventricular dilation, diffuse hypokinesia and LVEF
of 23%. Magnetic resonance angiography revealed 75% stenosis
of the left common carotid artery, complete occlusion of the
left subclavian artery and 80% stenosis of the descending thor-
acic aorta. According to the 2010 EULAR/PRINTO/PRESS classifi-
cation criteria the diagnosis of TA was established and
induction therapy with pulse methylprednisolone in combin-
ation with cyclophosphamide (0.5-1 g/m2/month, for 6 months)
was initiated followed by maintenance therapy with oral corti-
costeroids (prednisone 1.6 mg/kg/day). Poor clinical and echo-
cardiographic improvement was obtained (LVEF 30%) and
unfortunately the patient was lost to follow-up. Database litera-
ture search identified four cases of heart failure as chief mani-
festation of childhood TA. All patients were females.
Ecocardiography showed decreased LVEF in all cases, with a
mean LVEF of 28%. The most common vascular anomaly identi-
fied on computed tomography or magnetic resonance angiog-
raphy was severe stenosis or occlusion of the descending aorta.
Angiography was available in two patients and revealed a
Numano’s type III TA. Two patients benefited from transcatheter
stent implantation with marked improvement of the cardiac
function. One patient underwent bypass grafting but was lost
to follow-up. Treatment with Tocilizumab 8 mg/kg/monthly
proved to be effective and safe in one case report.
Conclusion: Severe stenosis of the thoracic aorta leading to heart
failure in children is rare and difficult to treat. In these cases gluco-
corticoids and conventional immunosuppressive agents alone are
not able to induce remission and improve cardiac function. More ag-
gressive strategies such as surgical interventions, angioplasty and
biological therapy have shown to be superior in preserving heart
function.
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Introduction: Juvenile morphea is not always a dermatological disease
only of aestethic concern, as it may be associated with systemic diseases.
Objectives: To present a case of systemic lupus erythematosus (SLE)
in a patient with an extensive morphea in the early childhood.
Methods: A 27-year patient, with an extensive morphea at the age of 6
and a SLE diagnosed at the age of 18 years, was referred to our tertiary
unit for altered clinical status and the assessment of recent-onset arter-
ial hypertension and right lower limb swelling.
Results: Clinical examination and further investigations revealed
polyserositis including pericarditis, hepatosplenomegaly and no
deep venous thrombosis. Laboratory showed antinuclear anti-
bodies with anti-dsDNA, positive anti-Scl-70 antibodies, C3 and
C4 consumption, anemia (7.8 g/dL), thrombocytopenia (65 000
Plt/mmc), increased D-dimers and a nephrotic-range proteinuria
(6 g/24 hours). A higher ferritin (675 mg/dL, normal < 450 mg/dL)
and rare schistocytes on the blood smear were noted. The video-
capillaroscopy did not reveal megacapillaries. The clinical picture
of the nephrotic syndrome was modified by the apparently
normal-looking skin (except from a slight hyperpygmentation) in-
volving the whole left lower limb, actually not distensible due to
the former morphea. She was anticoagulated, treated with cyclo-
phosphamide (Eurolupus scheme), hydroxychloroquine, low-dose
prednisone, angiotensin-converting enzyme inhibitors and albu-
min, with slow improvement. Two months later, before the end
of the initial cure, an initial unplanned pregnancy was lost. After
azathioprine, hydroxychloroquine and fraxyparine, she successfully
conceived a healthy babygirl, born at term, without complications
for the mother. She is currently well, on azathioprine, hydroxy-
chloroquine, low-dose aspirin and vitamin D.
Conclusion: Lower-limb morphea in childhood may modify the clinical
appearance of a bilateral edematous syndrome, even when the skin is not
much modified. Localized scleroderma may be accompanied by anti-Scl70
antibodies, even in the absence of a full systemic sclerosis picture. Informed
consent to publish has been obtained from the patient/parent/guardian.
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